18,489 Shares in IQVIA Holdings Inc. $IQV Purchased by Brandes Investment Partners LP

Brandes Investment Partners LP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,489 shares of the medical research company’s stock, valued at approximately $2,914,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Clal Insurance Enterprises Holdings Ltd boosted its holdings in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 131 shares during the period. Trust Co. of Toledo NA OH purchased a new stake in shares of IQVIA during the second quarter valued at $39,000. J.Safra Asset Management Corp grew its holdings in shares of IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the last quarter. Rothschild Investment LLC increased its stake in IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after buying an additional 124 shares during the period. Finally, NewSquare Capital LLC lifted its holdings in IQVIA by 185.3% during the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Citigroup upped their target price on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. HSBC raised IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. BMO Capital Markets started coverage on IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target on the stock. Morgan Stanley raised their price target on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $241.44.

IQVIA Trading Down 1.2%

Shares of NYSE IQV opened at $225.76 on Wednesday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $234.29. The business has a fifty day moving average price of $211.67 and a 200 day moving average price of $185.28. The stock has a market capitalization of $38.45 billion, a P/E ratio of 30.97, a price-to-earnings-growth ratio of 2.56 and a beta of 1.37. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.